

GENSIGHT BIOLOGICS
Société Anonyme au capital de 5,886,358.15 euros
Siège social : 74, rue du Faubourg Saint Antoine, 75012 Paris
751 164 757 R.C.S. Paris

INFORMATION REGARDING THE NOMINATION OF
FRANÇOISE DE CRAECKER FOR THE POSITION OF DIRECTOR SUBMITTED TO
THE ANNUAL SHAREHOLDERS' MEETING ON MAY 19, 2026

COMMONLY USED NAME: DE CRAECKER Françoise

ADDRESS: 26 Avenue du Yorkshire – Woluwé Saint Lambert – 1200 Belgique

DATE AND PLACE OF BIRTH: Ixelles (Belgium), December 22, 1961

**PROFESSIONAL REFERENCES AND PROFESSIONAL ACTIVITIES PERFORMED
IN OTHER COMPANIES OVER THE PAST FIVE YEARS:**

Françoise de Craecker, led the EMEA (Europe, Middle East & Africa) region at AveXis, further acquired by Novartis. She built from scratch the multifunctional team launching Zolgensma, the first one-shot Gene Therapy for the treatment of Spinal Muscular Atrophy, in the EMEA region. She paved the way for the approval, distribution, market access and commercialization, working with authorities on innovative funding pathways and early access. She also established a wide presence in the main European markets and a network of distributors in the Middle East and other European countries. Prior to joining AveXis, Mrs. de Craecker was leading EMEA operations for Raptor Pharmaceuticals (later acquired by Horizon and Chiesi) at the critical phase of a shift from R&D to commercialization of their lead product in Cystinosis, followed by the launch of their acquired product in Cystic Fibrosis. Before that, she was at Shire Human Genetics for 14 years. Originally, she was part of the team launching the first Orphan Drug approved in Europe. She then took different positions of increasing responsibilities and led various strategic and operational teams, locally and globally based in different European countries and USA. Mrs. de Craecker holds a Master's in Science from the Faculty of Medicine of the University of Leuven (Belgium).

Position and offices held as of the date of this Document:

- Independent director at X4 Pharmaceuticals, Member of the **Audit Committee** and the Remuneration Committee.
- Non Executive Director in the Board of Kyowa Kirin International Chair of the Compensation Committee and Member of the **Audit Committee**.

POSITIONS OR ROLES HELD WITH THE COMPANY OVER THE PAST FIVE YEARS:

Director of Gensight, Chair of the Compensation Committee, and Member of the Nominations Committee and the Transactions Committee.

NUMBER OF SHARES IN THE COMPANY HELD: 45,000